RACHAEL DRAKE: Open Payments
NPI 1831118421 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,185 in 56 payments from 16 companies in 2025. Trend: 2023 $1,310 · 2024 $1,090 · 2025 $1,185
Food & beverage: $1,185
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $276 |
| Madrigal Pharmaceuticals | 6 | $216 |
| Gilead Sciences, Inc. | 4 | $107 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $96 |
| GENZYME CORPORATION | 3 | $79 |
| Ardelyx, Inc. | 3 | $70 |
| Janssen Biotech, Inc. | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Intercept Pharmaceuticals, Inc. | 3 | $45 |
Products named: REZDIFFRA, RINVOQ, DUPIXENT, XIFAXAN, IBSRELA, TREMFYA, MAVYRET, VOQUEZNA.
Industry payments across IN — which companies pay providers there.
